Despite these limitations, our findings provide a robust foundation for further investigation into Cryptotanshinone as the potential therapeutic agent, particularly in targeting the GCNT2 pathway to improve PCOS management. The gene discussed is GCNT2; the disease is polycystic ovary syndrome.